One of the vaccines that provides particularly good protection against COVID-19 is BNT162b2 from Mainz-based biotech company BioNTech. To scale-up the manufacturing capacity further, BioNTech had just acquired a new production facility from Novartis and needed to rapidly transform the plant into a COVID-19 vaccine facility. 

Entire process flow controlled and orchestrated using Siemens products: 

• Opcenter Execution Pharma MES to orchestrate subsystems and processes, and analyze their quality. Production processes can be optimized and managed automatically 
• All systems were automated using the SIMATIC PCS 7 process control system. 
• Other products used include network technology, WLAN access points, communication technology and the TIA Portal engineering framework. 

Project Lightspeed, Marburg, Germany